TY - JOUR
T1 - Src and podoplanin forge a path to destruction
AU - Krishnan, Harini
AU - Miller, W. Todd
AU - Blanco, Francisco J.
AU - Goldberg, Gary S.
N1 - Funding Information:
This study was supported by grants from Fondo de Investigación Sanitaria RETIC-RIER-RD16/0012/0002 , PRB2-ISCIII-PT13/0001 , and PI16/02124 integrated in the National Plan for Scientific Program, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of Research-European Regional Development Fund (FEDER) ‘A way of making Europe’. F.J.B. was supported partially by Programa Intensificacion ISCIII ( INT16/00222 ). The authors are also grateful for funding from the Osteopathic Heritage Foundation and the New Jersey Health Foundation to GSG and NIH grant CA58530 to WTM.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/1
Y1 - 2019/1
N2 - Cancer and arthritis present an enormous challenge to society. They share pathogenic pathways that involve extracellular matrix degradation, tissue invasion, and inflammation. Most cancer and arthritis treatments affect normal cell function to cause significant adverse effects in patients. Specific pathways that promote cancer and arthritis progression must be elucidated to design more targeted and effective therapeutics. The Src kinase and podoplanin (PDPN) receptor are upregulated in cancer cells, fibroblasts, synoviocytes, and immune cells that increase tissue invasion and inflammation to promote both cancer and arthritis. In this review, we discuss how Src and PDPN forge a path to tissue destruction, and how they can serve as targets for therapeutics to combat cancer and arthritis.
AB - Cancer and arthritis present an enormous challenge to society. They share pathogenic pathways that involve extracellular matrix degradation, tissue invasion, and inflammation. Most cancer and arthritis treatments affect normal cell function to cause significant adverse effects in patients. Specific pathways that promote cancer and arthritis progression must be elucidated to design more targeted and effective therapeutics. The Src kinase and podoplanin (PDPN) receptor are upregulated in cancer cells, fibroblasts, synoviocytes, and immune cells that increase tissue invasion and inflammation to promote both cancer and arthritis. In this review, we discuss how Src and PDPN forge a path to tissue destruction, and how they can serve as targets for therapeutics to combat cancer and arthritis.
UR - http://www.scopus.com/inward/record.url?scp=85051750925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051750925&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2018.07.009
DO - 10.1016/j.drudis.2018.07.009
M3 - Review article
C2 - 30077780
AN - SCOPUS:85051750925
SN - 1359-6446
VL - 24
SP - 241
EP - 249
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 1
ER -